Brief: Bridgebio Submits NDA To FDA For Encaleret For Individuals Living With ADH1
12/05/2026 13:55
May 12 (Reuters) - BridgeBio Pharma Inc BBIO.O: BRIDGEBIO SUBMITS NDA TO FDA FOR ENCALERET FOR INDIVIDUALS LIVING WITH ADH1 BRIDGEBIO PHARMA INC - ENCALERET MAY BE ELIGIBLE FOR PRIORITY REVIEW; U.S. LAUNCH ANTICIPATED EARLY 2027 BRIDGEBIO PHARMA INC - TO SUBMIT MAA TO EMA FOR ENCALERET IN ADH1 IN SECOND HALF 2026 BRIDGEBIO PHARMA INC - TO INITIATE PHASE 3 RECLAIM-HP STUDY OF ENCALERET IN CHRONIC HYPOPARATHYROIDISM SUMMER 2026 Source text: ID:nGNX8pXrbp Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels